Confident AstraZeneca gets off to a good start in 2019
Brisk first quarter trading has given UK drugmaker AstraZeneca (LSE: AZN) a better-than-expected revenue figure of $5.5 billion for the first three months of 2019, up 6% from the same period last year.
Following Generally Accepted Accounting Principles (GAAP), AstraZeneca booked a profit of $1.1 billion, giving an earnings per share (EPS) figure of $0.47, a 75% increase on the first quarter of 2018.
The firm, which announced at the start of the year it had finally returned to growth, has reaped rewards from a continued focus on oncology and emerging markets, particularly China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze